Rise Reforming develops technology to convert stranded biogas, sourced from wastewater treatment plants, farms, and landfills, into chemicals. The process aims to produce chemicals like dimethyl ether (DME), methanol, and dimethyl carbonate (DMC) on-site, reducing reliance on fossil fuels for chemical production.
The company closed a $650,000 pre-seed funding round in March 2026. This funding supported the completion of the proof-of-concept, which involved over 1800 hours of stable syngas production. Rise Reforming is now preparing to implement its technology with live biogas, with pilot plant designs ready.
Rise Reforming has signed a binding supply agreement and multiple Memoranda of Understanding (MOUs) with biogas producers. Additionally, the company secured a conditional DME offtake agreement for its first commercial unit, indicating progress towards market entry for its chemical products.
The company's technology is designed to be modular, fitting within a shipping container for rapid and in-situ deployment. This modularity allows for scalability and aims to provide a price-competitive alternative to petrochemical-derived chemicals and existing green methanol and DMC options.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.
One email a day. Unsubscribe in one click, any time.
Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.
▶ Play today's briefNew every morning, and the back catalogue is archived by date.
Rise Reforming, a Y Combinator S26 startup, converts waste biogas from sources like wastewater plants and farms into chemicals such as dimethyl ether (DME), methanol, and dimethyl carbonate (DMC). The company has secured $650,000 in pre-seed funding, completed proof-of-concept, and signed a binding supply agreement and a conditional DME offtake agreement.